Application Number: 10-2021-0006947
Title of Invention: Pharmaceutical composition for treating TRPV1 activation-mediated diseases
With the approval of this national patent, RudaCure Inc. has taken one step closer to commercializing RCI002 for divers pain conditions.
L'entreprise prévoit de continuer expanding its patent portefeuille in line with its patent strategy as it secures additional pipelines à l'avenir.